NEW YORK, March 12, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics
Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI),
Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc.
(NASDAQ: OHRP). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
ARIAD Pharmaceuticals, Inc. Analyst
Notes
On February 25, 2014, ARIAD
Pharmaceuticals, Inc. (Ariad) reported Q4 2013 and full-year 2013
financial results. In Q4 2013, the Company's revenue totaled
$8.4 million, compared with
$74,000 in Q4 2012, while full-year
2013 revenue totaled $45.6 million,
compared with $0.6 million in full
year 2012. Q4 2013 net loss was $74.2
million, or $0.40 loss per
diluted share, compared to a net loss of $60.5 million, or $0.36 loss per diluted share, in Q4 2012.
Full-year 2013 net loss was $274.2
million, or $1.49 loss per
diluted share, compared to a net loss of $220.9 million, or $1.34 loss per diluted share, for full-year 2012.
"I am extremely pleased with the commercial and R&D progress we
made in 2013, especially ending the year with Iclusig commercially
available to refractory Philadelphia-positive leukemia patients in
the United States. We are off to a
strong start with our re-launch in the U.S. and are building
momentum in Europe," said
Harvey J. Berger, M.D., Chairman and
CEO of ARIAD. The full analyst notes on ARIAD Pharmaceuticals, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03122014/ARIA/report.pdf
--
NewLink Genetics Corporation Analyst
Notes
On March 7, 2014, NewLink Genetics
Corporation (NewLink) announced that following the completion of
first interim analysis of the Phase 3 IMPRESS clinical study of
algenpantucel-L for patients with surgically resected pancreatic
cancer, the Company's independent data safety monitoring committee
recommends the continuation of the study. "As we have previously
emphasized, continuation of this study was an anticipated outcome
considering the high statistical threshold assigned to this first
interim analysis under the special protocol assessment," said Dr.
Charles Link, Chairman and CEO of
NewLink. The full analyst notes on NewLink Genetics Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/03122014/NLNK/report.pdf
--
Puma Biotechnology, Inc. Analyst
Notes
On March 5, 2014, Puma
Biotechnology, Inc. (Puma Biotechnology) announced the schedule of
an oral presentation to be held at the American Association for
Cancer Research (AACR) Annual Meeting 2014, in which the results of
the Phase II clinical trial of its investigational drug PB272
(neratinib) for the neoadjuvant treatment of breast cancer (I-SPY2
TRIAL) will be presented. The AACR event will be held on
April 5-9, 2014 in San Diego, California, whereas the related
presentation entitled "Neratinib plus Standard Neoadjuvant Therapy
for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2
TRIAL" will take place on April 7,
2014 between 10:30 a.m. and 12:30
p.m. PDT, during the session - "Clinical Trials Symposium:
Biomarker Driven Clinical Trials." The full analyst notes on Puma
Biotechnology, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03122014/PBYI/report.pdf
--
Theravance, Inc. Analyst Notes
On March 3, 2014, Theravance, Inc.
(Theravance) announced that its intention to separate its
businesses into two independent, publicly traded companies is
expected to be completed in Q2 2014. Theravance also informed that
it has entered into a series of agreements with Theravance
Biopharma, Inc., and Glaxo Group Limited (GSK) clarifying how the
companies will execute the spin-off and operate following the
spin-off. "We continue to believe this separation will provide
investors with the opportunity to unlock potential value from two
different sets of assets, better align employee incentives and
provide the opportunity for significant capital returns.
Additionally, I am pleased that we recently entered into a series
of agreements with GSK clarifying how the companies will operate
following the separation and with the goal of bringing a portfolio
of new respiratory products for the treatment of COPD and asthma to
patients suffering from these debilitating diseases," said
Rick E. Winningham, CEO of
Theravance. The full analyst notes on Theravance, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03122014/THRX/report.pdf
--
Ohr Pharmaceutical, Inc. Analyst
Notes
On March 3, 2014, Ohr
Pharmaceutical, Inc. (Ohr) teamed up with Cold Spring Harbor
Laboratory (CSHL) to announce the establishment of DepYmed Inc., a
new joint venture to develop trodusquemine and related analogs. The
Company informed that the new joint venture will be a private
entity, initially with equal ownership by Ohr and CSHL. "Cold
Spring Harbor Laboratory is a world class research center that has
a track record of establishing successful commercial ventures in
the biopharma space," said Irach Taraporewala, President and CEO of
Ohr. "We are very pleased to be working with Dr. Nicholas Tonks who is one of the leading
authorities on the protein tyrosine phosphatase (PTP) family of
enzymes. Dr. Tonks discovered PTP1B, the primary target for
trodusquemine. Setting up this joint venture is the optimal way to
create shareholder value from this exciting asset and enable it to
obtain the appropriate resources. At the same time, Ohr remains
focused on the execution of our core strategy to develop novel
ophthalmology products." The full analyst notes on Ohr
Pharmaceutical, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03122014/OHRP/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review